Kaempferol is a natural flavonoid found in many fruits and vegetables, and there is emerging scientific interest in its potential to support diabetic retinopathy. Preclinical studies, primarily in animal models and cell cultures, have shown that kaempferol exhibits antioxidant, anti-inflammatory, and anti-angiogenic properties. These mechanisms are relevant because diabetic retinopathy involves oxidative stress, inflammation, and abnormal blood vessel formation in the retina.

For example, several studies have demonstrated that kaempferol can reduce oxidative damage and inhibit the expression of vascular endothelial growth factor (VEGF), a key contributor to retinal neovascularization in diabetic retinopathy. Some animal studies report that kaempferol administration ameliorates retinal damage, reduces vascular leakage, and suppresses inflammatory cytokines in diabetic models. However, these findings are limited to preclinical evidence; as of now, there are no published clinical trials in humans directly evaluating kaempferol for the prevention or treatment of diabetic retinopathy.

In summary, the use of kaempferol for diabetic retinopathy is supported by basic scientific research and animal studies, but lacks robust clinical validation. Its use is not based on traditional medicine practices for this specific condition. More rigorous clinical studies are needed to determine its efficacy and safety in humans.